Skip to main content
PRAX logo

Praxis Precision Medicines, Inc. (PRAX) Stock: Price, Forecast & Analyst Target

Praxis Precision Medicines, Inc. (PRAX) — MoonshotScore 60/100 (Fair band), calculated Nov 18, 2026. Price $310.90 (+1.87%), as of the Nov 19, 2026 trading session; market cap $8.69B. Expected results Feb 18, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 11.66× (cash as of Sep 30, 2026) · expected results Feb 18, 2027

$310.90 +$5.71 (+1.87%) Market Cap $8.69B

Praxis Precision Medicines, Inc. · PRAX · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Praxis Precision Medicines is a clinical-stage developer of therapies for central nervous system disorders linked to abnormal neuronal activity, not a commercial drug company with recurring product sales. Its value rests on whether a broad investigational pipeline can produce approvals or partnership economics before research spending consumes the financial cushion.

Price as of Nov 19, 2026

Key Statistics

60 of 100

MoonshotScore v2 · Praxis Precision Medicines (PRAX)

Fair
Business Quality Average (44)
Financial Safety Sound (79)
Valuation Full (53)
Growth Durability Fading (21)
Momentum Rising (78)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Sound; Valuation: Full; Growth Durability: Fading; Momentum: Rising.

  • EPS beat 4 of the last 8 reports
  • Altman Z 95.69 · Piotroski F 2
  • ROE -29.4% · ROA -27.4% · current ratio 14.53 · earnings yield -4.0% · free-cash-flow yield -3.8%

Holding back: soft growth

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PRAX (57 recorded, newest six shown)
RecordedScoreBand
59Fair
59Fair
58Fair
58Fair
60Fair
60Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$310.90
Change on the day+1.87%
52-week range$160.11–$392.70
Market capitalisation$8.69B—
Shares traded on the day630.3K
Beta (volatility vs the S&P 500)2.84

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $168, high $376, latest $311. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $376 $168 high $376 Feb 19, 2026 · Earnings results · reported below the recorded estimate · close $3351May 7, 2026 · Earnings results · reported above the recorded estimate · close $3302Aug 6, 2026 · Earnings results · reported above the recorded estimate · close $3613Nov 9, 2026 · Earnings results · reported above the recorded estimate · close $2784 Oct 17, 2025 Nov 19, 2026 · $311 $190Oct 17, 2025$199Oct 31, 2025$186Nov 14, 2025$196Nov 28, 2025$269Dec 12, 2025$269Dec 26, 2025$288Jan 9, 2026$312Jan 23, 2026$320Feb 6, 2026$335Feb 20, 2026$311Mar 6, 2026$298Mar 20, 2026$310Apr 2, 2026$343Apr 17, 2026$324May 1, 2026$343May 15, 2026$350May 29, 2026$267Jun 12, 2026$328Jun 26, 2026$325Jul 10, 2026$325Jul 24, 2026$361Aug 7, 2026$376Aug 21, 2026$352Sep 4, 2026$299Sep 18, 2026$296Oct 2, 2026$242Oct 16, 2026$286Oct 30, 2026$328Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Praxis Precision Medicines (PRAX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Moderate
Valuation Neutral
Growth Durability Weak
Momentum Moderate

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Praxis Precision Medicines (PRAX), and what does it report?

Short answer · as of

Praxis designs compounds that alter neuronal signaling through GABAA receptors, calcium channels and sodium currents, alongside antisense programs for genetically defined epilepsies.

Clinical development and licensing collaborations are the operating work; patients are not yet generating a recurring product-revenue stream.

Reported revenue has instead come from license and upfront payments, and recent periods recorded none. The income statement therefore measures the cost of advancing the pipeline, with research and development dominating expenses and recurring losses reflecting investment in investigational assets rather than weak demand for an established medicine.

2 · Latest results

What do the latest results show for Praxis Precision Medicines (PRAX)?

Short answer · as of

Against analyst estimates the company has EPS beat 4 of the last 8 reports.

The latest quarter remained pre-revenue and deeply loss-making, but the net and operating losses narrowed from the preceding period as research spending eased. Operating cash use also moderated, although it remained well above the pace seen earlier in the historical series.

Recent reported losses have come in ahead of analyst expectations, yet that comparison says little about clinical or commercial progress. The broader annual record shows research spending expanded sharply while the net loss widened, so the latest moderation has not yet established a sustained change in the cost base.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · R&D
$64.20M Sep 30, 2026
Latest quarter · SG&A
$42.71M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$106.91M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not available$64.20M$42.71M−$106.91M
Jun 30, 2026Not available$69.42M$27.49M−$96.90M
Mar 31, 2026Not available$77.99M$27.87M−$105.86M
Dec 31, 2025Not available$77.51M$19.54M−$97.04M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue estimate
$130,769 Nov 9, 2026
Latest report · EPS vs estimate
Above estimate Nov 9, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 9, 2026Not available$130,769−$3.2300−$3.5400
Aug 6, 2026Not availableProvider row rejected−$2.8700−$3.6700
May 7, 2026Not available$100,000−$3.2000−$3.5800
Feb 19, 2026Not available$66,667−$3.5000−$3.1259
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

3 · Financial strengths and risks

What are the financial strengths and risks for Praxis Precision Medicines (PRAX)?

Short answer

Cash and short-term investments were $745.32M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$81.74M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.

Cash and short-term investments greatly exceed debt and current liabilities, while liquidity ratios indicate ample near-term coverage. At the recent operating and capital-spending pace, the available balance supports multiple years of development, giving Praxis meaningful room to fund trials without immediate dependence on operating revenue.

That cushion is not the same as self-funding. Operations continue to consume cash, the latest balance declined from the preceding quarter, and the market value stands far above net cash; valuation therefore depends primarily on investigational assets creating future economic value. Clinical failure, regulatory delay or an inability to secure attractive licensing terms would leave substantial research spending without a product-sales base, while the wide spread in longer-range revenue estimates shows how differently that conversion can unfold.

Data-derived red flags

  • Negative return on equity (-29.4%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
−$81.74M Sep 30, 2026
Previous quarter · operating cash flow
−$77.64M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026−$81.74M−$780,000
Jun 30, 2026−$77.64M−$240,000
Mar 31, 2026−$86.05M−$60,000
Dec 31, 2025−$77.26M$0.00
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Praxis Precision Medicines (PRAX)?

Short answer · as of

The next earnings report is expected on Feb 18, 2027. The number it tests is the $-13.48 EPS analysts carry for it.

The next scheduled report should be read for the direction of research spending, operating cash use and the cash balance. Continued moderation across those measures would extend financial flexibility; renewed acceleration would shorten the time available for the pipeline to create value.

Revenue deserves a different test from that applied to a commercial drugmaker. A reappearance of license or upfront payments would reflect partnership economics, while continued absence of revenue would remain consistent with the present clinical-stage model. Pipeline disclosures in regulatory filings matter more than small swings around loss estimates because approvals and collaborations are the route from research expense to durable economics.

What the records here don't tell us

  • No quarterly income statement is held for PRAX.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Praxis Precision Medicines compare with its peers?

Short answer

Praxis Precision Medicines's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

The relevant comparison is with clinical-stage central nervous system developers rather than profitable pharmaceutical companies. Praxis combines small molecules that modulate distinct neuronal channels and receptors with antisense programs aimed at genetically defined epilepsies, supported by licensing and research alliances.

That breadth spreads scientific effort across different mechanisms, but it does not create diversification comparable with marketed products. Current financial performance is still driven by pipeline spending and episodic collaboration revenue, so comparisons based on sales growth or conventional earnings multiples miss what the business presently produces.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$156.23 Nov 18, 2026$6.35B64 5-pillar Nov 18, 2026
Praxis Precision Medicines (PRAX) — this page$310.90$8.69B60
Xenon Pharmaceuticals Inc. (XENE) Named competitor$37.56 Nov 19, 2026$3.69B56 5-pillar Nov 18, 2026
Immunovant, Inc. (IMVT) Named competitor$32.52 Nov 19, 2026$6.73B25 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$162.00 – $1201.00
Consensus target
$656.60
Median target
$616.00
Revenue estimate
$634,320
EPS estimate
$-13.48

Consensus record · Captured .

Measured against a quoted price of $310.90 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 8, 2026

Transactions
34
Identified insiders
9
Purchases
0
Sales
12
Other transactions
22

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
358 Period end Sep 30, 2026
Previous quarter · holders
332 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Janus Henderson Group Ltd.3,449,950
Fmr LLC2,637,857
Blackrock, INC.2,232,814
Perceptive Advisors LLC2,024,781
Baker Bros. Advisors LP1,753,198

Tracked investors

Which of the 16 named investors we follow held PRAX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PRAX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Praxis Precision Medicines (PRAX)?

Read these with our analysis →

What Investors Ask About Praxis Precision Medicines (PRAX) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What is Praxis trying to change with its GABAA program?

The program uses an extrasynaptic-preferring positive allosteric modulator intended to alter inhibitory neuronal signaling, with development directed toward major depressive disorder and perimenopausal depression.

How does Praxis approach essential tremor?

Praxis is evaluating a selective inhibitor of T-type calcium channels, making control of abnormal neuronal activity the therapeutic mechanism rather than treatment of a commercial product market.

Why can Praxis report no revenue while advancing central nervous system medicines?

Its candidates remain investigational, so development activity appears mainly as research expense. Historical revenue has come from license and upfront payments rather than recurring medicine sales.

What distinguishes Praxis’s antisense epilepsy work?

The portfolio includes antisense development aimed at gain-of-function genetic epilepsies, complemented by research and licensing relationships with Ionis Pharmaceuticals and the Florey Institute. This adds a genetically targeted modality alongside the company’s small-molecule channel and receptor programs.

What is the PRAX stock price today?

The last price recorded for Praxis Precision Medicines, Inc. (PRAX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the PRAX price target?

The analyst consensus price target for Praxis Precision Medicines, Inc. (PRAX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 69 figures on this page — 1 from SEC filings and earnings calls, 59 from Financial Modeling Prep (FMP), 6 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Cash, investments and debt; Cash runway cross-check (ours)
  • 1. What is Praxis Precision Medicines (PRAX), and what does it report?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Praxis Precision Medicines (PRAX)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Praxis Precision Medicines (PRAX)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Cash against market value; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Analyst revenue and earnings estimates (average); Business description
  • 4. What should you watch next at Praxis Precision Medicines (PRAX)?: Next earnings report; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Revenue by segment; Reported versus estimated, last 8 quarters; Recent SEC filings; Most recent periodic reports; Business description
  • 5. How does Praxis Precision Medicines compare with its peers?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set
  • FAQ: What is Praxis trying to change with its GABAA program?: Business description
  • FAQ: How does Praxis approach essential tremor?: Business description
  • FAQ: Why can Praxis report no revenue while advancing central nervous system medicines?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: What distinguishes Praxis’s antisense epilepsy work?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold PRAX

Funds in our ETF coverage that list PRAX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Global X - Genomics & Biotechnology ETF (GNOM)6.23%
iShares Neuroscience and Healthcare ETF (IBRN)5.61%
State Street SPDR S&P Biotech ETF (XBI)1.57%
iShares Russell 2000 Value ETF (IWN)0.51%
Invesco Russell 2000 Dynamic Multifactor ETF (OMFS)0.30%